Loading...
Loading...
- Baxter International Inc BAX Q2 revenue of $3.1 billion, in line with the consensus, increased 14% on a reported basis, 9% on a constant currency basis, and 8% on an operational basis.
- Adjusted EPS of $0.80 increased 25% and surpassed the estimate of $0.75.
- Among Baxter's product categories, growth was led by BioPharma Solutions, Advanced Surgery, and Medication Delivery, which each delivered double-digit growth.
- Acute Therapies grew at low single digits on a reported basis and declined mid-single digits at constant currency rates, reflecting a challenging comparison due to surging product demand this time last year related to the COVID-19 pandemic.
- The gross margin expanded from 38.2% to 39.8%, and the operating margin improved from 12.2% to 13.7%.
- Outlook: Baxter expects full-year 2021 sales growth of approximately 8% on a reported basis, 5% to 6% on a constant currency basis, and 4% to 5% on an operational basis. It expects an adjusted EPS of $3.49 - $3.55, versus the $3.40 consensus.
- For Q3, the Company sees sales growth of approximately 7% on a constant currency basis, 6% on an operational basis. It expects an adjusted EPS of $0.93 to $0.95.
- The Company is reportedly in talks to acquire Hill Rom.
- Price Action: BAX shares closed at $81.91 on Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in